BR0014222A - Method and compositions for inhibiting adhesion formation - Google Patents

Method and compositions for inhibiting adhesion formation

Info

Publication number
BR0014222A
BR0014222A BR0014222-0A BR0014222A BR0014222A BR 0014222 A BR0014222 A BR 0014222A BR 0014222 A BR0014222 A BR 0014222A BR 0014222 A BR0014222 A BR 0014222A
Authority
BR
Brazil
Prior art keywords
compositions
adhesion formation
inhibiting
inhibiting adhesion
methods
Prior art date
Application number
BR0014222-0A
Other languages
Portuguese (pt)
Inventor
David A Cheresh
Bruce Lessey
Original Assignee
Scripps Research Inst
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ North Carolina filed Critical Scripps Research Inst
Publication of BR0014222A publication Critical patent/BR0014222A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO E COMPOSIçõES PARA INIBIR A FORMAçãO DE ADESãO". A presente invenção refere-se a composições e métodos para inibir ou melhorar a formação de adesão no pós operatório/pós cicatrização em pacientes. As referidas composições e métodos utilizam uma molécula antagonista que bloqueia ou inibe a ligação da integrina alfa V beta 3 a uma proteína de matriz extracelular tal como fibronectina."METHOD AND COMPOSITIONS FOR INHIBITING ADHESION TRAINING". The present invention relates to compositions and methods for inhibiting or improving postoperative / post-healing adhesion formation in patients. Said compositions and methods utilize an antagonist molecule that blocks or inhibits the binding of alpha V beta 3 integrin to an extracellular matrix protein such as fibronectin.

BR0014222-0A 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation BR0014222A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
BR0014222A true BR0014222A (en) 2003-02-25

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014222-0A BR0014222A (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Country Status (9)

Country Link
EP (1) EP1223962A4 (en)
JP (1) JP2003509468A (en)
KR (1) KR20020048941A (en)
CN (1) CN1399554A (en)
AU (1) AU781442B2 (en)
BR (1) BR0014222A (en)
CA (1) CA2384812A1 (en)
MX (1) MXPA02003079A (en)
WO (1) WO2001021196A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (en) 2007-08-15 2013-09-02 Canadian Blood Services Monoclonal antibodies against BETA3 integrins.
CA3030111A1 (en) 2016-07-13 2018-01-18 Mochida Pharmaceutical Co., Ltd. Adhesion-preventing composition
CN111936175A (en) * 2018-01-15 2020-11-13 持田制药株式会社 Anti-adhesion composition
KR102318958B1 (en) * 2019-08-08 2021-10-27 고려대학교 산학협력단 Pharmaceutical Composition for Preventing or Treating Tissue Adhesion Comprising Integrin α2β1 Inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2001513559A (en) * 1997-08-25 2001-09-04 ブレム，ハロルド Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
KR20020048941A (en) 2002-06-24
EP1223962A1 (en) 2002-07-24
MXPA02003079A (en) 2004-04-21
EP1223962A4 (en) 2004-01-21
JP2003509468A (en) 2003-03-11
WO2001021196A1 (en) 2001-03-29
AU7985000A (en) 2001-04-24
AU781442B2 (en) 2005-05-26
CN1399554A (en) 2003-02-26
CA2384812A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
BR0211888A (en) Materials and Methods for Promoting Nerve Tissue Repair
BR0315589A (en) New compositions with chitinase activity
BR9714415A (en) Nitrogen-containing heterocycles replaced as p38 protein kinase inhibitors
ATE259215T1 (en) COMPOSITION FOR REGULATING SKIN APPEARANCE
DE60013098D1 (en) COMPOSITION FOR SKIN DISINFECTATION
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
BR9916879A (en) Composition and method for treating cancer using natural vegetable essential oils
BRPI0414918A (en) benzoimidazole compounds
DE50010115D1 (en) COMPOSITION AND METHOD FOR DETERMINING AIR
BRPI0416544A (en) gag binding protein
ATE547009T1 (en) COMPOSITIONS AND METHODS FOR PROMOTING BODY FAT LOSS
ATE293691T1 (en) MYOSTATIN GENE PROMOTER AND INHIBITION OF ITS ACTIVATION
BR0014860A (en) Methods for producing a target molecule in a transgenic animal and purifying the target molecule
BRPI0406596A (en) Methods for treating joint pain and improving sleep using an estrogen agonist / antagonist
BR9811923A (en) Compounds having neuronal activity
DE60313434D1 (en) METHOD AND COMPOSITIONS FOR TREATING HYPERPROLIFERATIVE STATES
DE60138552D1 (en) PEPTIDES WITH INTEGRIN BINDING MOTIVATION AND TREATMENT METHODS FOR MUSCLE DISEASES
PT1144365E (en) INHIBITORS OF THE ADHESION OF CELLS MEDIATED BY ALFA4BETA1
BR0014222A (en) Method and compositions for inhibiting adhesion formation
DE69825901D1 (en) VITAMIN E CONTAINING PLASTIC COMPOSITION FOR MEDICAL CONTAINERS AND METHODS FOR PROVIDING SUCH COMPOSITIONS AND CONTAINERS
BR0308584A (en) Androgenic pharmaceutical composition and method for treating depression
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE357255T1 (en) PLACENTA GROWTH FACTOR AS A TARGET FOR THE TREATMENT OF OSTEOPOROSIS
BR9810996A (en) Pharmaceutical composition
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.